Literature DB >> 18049033

Dilation of renal artery stenosis after administration of losartan.

Masayuki Tanemoto1, Kei Takase, Takayuki Yamada, Akihiro Satoh, Takaaki Abe, Sadayoshi Ito.   

Abstract

Transluminal angioplasty with a balloon catheter is effective to dilate renal artery stenosis (RAS) caused by fibromuscular dysplasia (FMD), but lesions resistant to the angioplasty exist. In this report, we describe the case of a young woman with RAS of FMD that was difficult to dilate even by cutting-balloon angioplasty. To facilitate the formation of a smooth intimal covering at the site of angioplasty, we administered losartan, an angiotensin receptor blocker, for 4 months after the angioplasty. Although re-stenosis was detected at 5 months after the angioplasty, the normotensive state continued without antihypertensives and the re-stenosis gradually dilated afterwards. The present case suggests the possibility of remodeling the renal artery during the normotensive state by administering losartan after the angioplasty.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18049033     DOI: 10.1291/hypres.30.999

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  3 in total

Review 1.  Non-Atherosclerotic Vascular Disease in Women.

Authors:  Lee Joseph; Esther S H Kim
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-09-14

2.  Brain Stem Hemorrhage in a 2-Year-10-Month-Old Child with Renovascular Hypertension Related to Fibromuscular Dysplasia.

Authors:  Yao-Min Hung; Ken-Pen Weng; Chu-Chuan Lin; Jer-Shyung Huang; Yee-Hsuan Chiou; Kai-Sheng Hsieh
Journal:  Acta Cardiol Sin       Date:  2015-11       Impact factor: 2.672

3.  Clinical and biochemical profiles suggest fibromuscular dysplasia is a systemic disease with altered TGF-β expression and connective tissue features.

Authors:  Santhi K Ganesh; Rachel Morissette; Zhi Xu; Florian Schoenhoff; Benjamin F Griswold; Jiandong Yang; Lan Tong; Min-Lee Yang; Kristina Hunker; Leslie Sloper; Shinie Kuo; Rafi Raza; Dianna M Milewicz; Clair A Francomano; Harry C Dietz; Jennifer Van Eyk; Nazli B McDonnell
Journal:  FASEB J       Date:  2014-04-14       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.